Bristol Myers Squibb (NYSE:BMY) Releases FY 2026 Earnings Guidance

Bristol Myers Squibb (NYSE:BMY) updated its FY 2026 earnings guidance on Thursday. The company provided EPS guidance of 6.750-7.000 for the period, compared to the consensus estimate of 6.310. The company issued revenue guidance of $49.0 billion-$50.0 billion, compared to the consensus revenue estimate of $47.3 billion.

Bristol Myers Squibb Stock Up 0.4%

Shares of Bristol Myers Squibb stock traded up $0.25 during trading on Friday, reaching $65.11. 6,748,458 shares of the company traded hands, compared to its average volume of 12,228,595. The company has a debt-to-equity ratio of 2.10, a current ratio of 1.42 and a quick ratio of 1.28. Bristol Myers Squibb has a 1-year low of $42.52 and a 1-year high of $65.66. The company has a 50 day moving average price of $57.90 and a 200-day moving average price of $58.29. The firm has a market capitalization of $132.97 billion, a PE ratio of 18.30, a P/E/G ratio of 0.18 and a beta of 0.23.

Bristol Myers Squibb (NYSE:BMY) last posted its quarterly earnings results on Thursday, July 30th. The biopharmaceutical company reported $2.04 EPS for the quarter, topping analysts’ consensus estimates of $1.60 by $0.44. Bristol Myers Squibb had a net margin of 15.01% and a return on equity of 64.87%. The business had revenue of $12.97 billion during the quarter, compared to analysts’ expectations of $11.74 billion. During the same period last year, the company posted $1.46 earnings per share. The business’s quarterly revenue was up 5.7% on a year-over-year basis. Bristol Myers Squibb has set its FY 2026 guidance at 6.750-7.000 EPS. As a group, equities research analysts expect that Bristol Myers Squibb will post 6.34 earnings per share for the current fiscal year.

Bristol Myers Squibb Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Monday, August 3rd. Investors of record on Thursday, July 2nd will be paid a dividend of $0.63 per share. This represents a $2.52 dividend on an annualized basis and a yield of 3.9%. The ex-dividend date of this dividend is Thursday, July 2nd. Bristol Myers Squibb’s dividend payout ratio is 70.79%.

Analysts Set New Price Targets

A number of brokerages have commented on BMY. Raymond James Financial reissued a “market perform” rating on shares of Bristol Myers Squibb in a research note on Monday. Cantor Fitzgerald reissued a “neutral” rating and issued a $59.00 price target (up from $54.00) on shares of Bristol Myers Squibb in a research report on Friday. Citigroup restated a “neutral” rating on shares of Bristol Myers Squibb in a report on Friday, May 1st. JPMorgan Chase & Co. raised their price objective on shares of Bristol Myers Squibb from $67.00 to $73.00 and gave the company an “overweight” rating in a research note on Friday. Finally, Weiss Ratings cut shares of Bristol Myers Squibb from a “hold (c+)” rating to a “hold (c)” rating in a report on Thursday, July 16th. Nine analysts have rated the stock with a Buy rating, twelve have given a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the company has a consensus rating of “Hold” and an average price target of $63.00.

Trending Headlines about Bristol Myers Squibb

Here are the key news stories impacting Bristol Myers Squibb this week:

• Positive Sentiment: Q2 results exceeded expectations: Bristol Myers reported adjusted EPS of $2.04 versus the $1.60 consensus and revenue of $12.97 billion versus estimates of $11.74 billion. Revenue increased 5.7% year over year, while EPS rose from $1.46 in the prior-year quarter. Bristol Myers raises 2026 forecast as Eliquis and newer medicines power results
• Positive Sentiment: 2026 outlook was raised: Management now expects full-year EPS of $6.75 to $7.00 and revenue of $49 billion to $50 billion, above consensus estimates of approximately $6.31 EPS and $47.3 billion in revenue. BMY Q2 earnings beat estimates and 2026 view raised
• Positive Sentiment: Growth products are gaining traction: Eliquis sales were a major contributor, while Camzyos, Reblozyl, Opdivo Qvantig, Breyanzi and other newer medicines helped the growth portfolio reach roughly 60% of revenue. Management also highlighted pipeline progress. Bristol-Myers Squibb Q2 2026 earnings call transcript
• Positive Sentiment: Analyst support improved: Truist reaffirmed its Buy rating and increased its price target from $65 to $70, implying additional upside from recent levels.
• Neutral Sentiment: Some analysts remain cautious, citing valuation after BMY’s recent rally and the need for continued execution to replace older products.
• Negative Sentiment: Risks remain: Legacy portfolio declines from patent expirations continue, while Opdivo declined and readouts for Milvexian and Cobenfy were delayed. Elevated put-option activity also indicates some investors are hedging downside risk.

Hedge Funds Weigh In On Bristol Myers Squibb

Institutional investors and hedge funds have recently bought and sold shares of the company. Darwin Wealth Management LLC bought a new stake in shares of Bristol Myers Squibb in the second quarter valued at $25,000. Swiss RE Ltd. purchased a new stake in Bristol Myers Squibb in the 4th quarter worth about $25,000. JPL Wealth Management LLC purchased a new stake in Bristol Myers Squibb in the 3rd quarter worth about $36,000. Turning Point Benefit Group Inc. bought a new stake in Bristol Myers Squibb in the 3rd quarter valued at about $40,000. Finally, Quarry LP purchased a new stake in Bristol Myers Squibb during the third quarter valued at about $48,000. 76.41% of the stock is owned by institutional investors.

About Bristol Myers Squibb

Bristol Myers Squibb is a global biopharmaceutical company headquartered in Princeton, New Jersey, focused on discovering, developing and delivering medicines for serious diseases. The company’s core activities include research and development, clinical development, manufacturing and commercialization of prescription pharmaceuticals across multiple therapeutic areas. BMS concentrates on advancing therapies in oncology, hematology, immunology, cardiovascular disease and specialty areas through both small molecules and biologics.

BMS’s marketed portfolio and late?stage pipeline reflect a strong emphasis on cancer and immune?mediated conditions.